Familial Dysautonomia Carrier Test: ELP1 Gene, Carrier Risk, and Results

A familial dysautonomia carrier test looks for disease-causing variants in the ELP1 gene, most often before pregnancy or early in pregnancy. Familial dysautonomia is a rare, serious nerve disorder inherited in an autosomal recessive pattern. A carrier has one altered ELP1 copy and one working copy and usually has no symptoms. The test becomes especially important when a person has Ashkenazi Jewish ancestry, a relative with familial dysautonomia, a known familial ELP1 variant, or a reproductive partner who is already known to be a carrier. Results may be positive, negative, uncertain, or occasionally inconclusive, and each requires a different response. A positive carrier result does not mean that the person has familial dysautonomia. It does mean that partner testing and genetic counseling can clarify the chance of an affected pregnancy and the available reproductive options. The test method also matters because a limited founder-variant panel can miss rare ELP1 variants that broader sequencing may detect.

• A positive carrier result usually means one pathogenic or likely pathogenic ELP1 variant was found; carriers are generally healthy.
• When both reproductive partners are ELP1 carriers, each pregnancy has a 25% chance of familial dysautonomia.
• The common Ashkenazi Jewish founder variant is ELP1 c.2204+6T>C, but rare disease-causing variants also occur.
• No fasting or medication changes are usually needed; testing commonly uses blood, saliva, or a cheek-swab sample.
• A negative result lowers carrier risk but does not reduce it to zero, especially after a limited-variant test.
• A positive or uncertain result should be reviewed with a genetics professional before pregnancy decisions are made.

Table of Contents

• What the ELP1 Carrier Test Checks
• Who Should Consider Testing
• How Testing Is Performed
• Understanding Positive, Negative, and Uncertain Results
• Pregnancy Risk When One or Both Partners Are Carriers
• Next Steps After a Carrier Result
• Test Limitations and Common Mistakes
• Questions to Ask Before and After Testing

What the ELP1 Carrier Test Checks

The test examines the ELP1 gene for variants that can cause familial dysautonomia, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndrome. ELP1 provides instructions for a protein involved in the development and continued function of sensory and autonomic nerves. These nerves help regulate blood pressure, heart rate, swallowing, digestion, tear production, temperature control, pain sensation, and breathing responses.

Familial dysautonomia occurs when a person inherits a disease-causing ELP1 variant from each parent. The condition is present from birth and can cause feeding and swallowing problems, reduced tears, repeated lung infections, blood pressure instability, vomiting crises, altered pain and temperature sensation, poor balance, progressive vision loss, and other complications. Carrier screening does not diagnose these symptoms. Its purpose is to identify healthy people who could pass an ELP1 variant to a child.

The best-known familial dysautonomia variant is c.2204+6T>C, historically described as IVS20+6T>C. It interferes with RNA splicing, the process cells use to assemble genetic instructions before making protein. This founder variant accounts for the great majority of affected people with Ashkenazi Jewish ancestry. Another recurrent ELP1 variant, c.2087G>C, has also been reported in this population, while other rare pathogenic variants occur across ancestries.

A laboratory may use one of several testing approaches:

• Targeted founder-variant testing checks only one or several well-known variants. It can be efficient when ancestry and family history strongly match those variants.
• Full-gene sequencing reads the protein-coding regions and nearby splice boundaries of ELP1 to look for many possible small variants.
• Deletion and duplication analysis looks for larger missing or extra segments that sequencing may not detect reliably.
• Expanded carrier screening includes ELP1 along with dozens or hundreds of other recessive and X-linked conditions.
• Targeted familial-variant testing checks for the exact variant already identified in a relative.

The distinction is important. A person who had only the common founder variant checked has not necessarily had comprehensive ELP1 testing. The laboratory report should state the method, the transcript used to name variants, the regions analyzed, and whether deletion and duplication analysis was included.

Carrier screening is a form of autosomal recessive carrier screening. It estimates reproductive risk; it does not predict whether a carrier will develop familial dysautonomia, because carriers generally do not have the disorder.

Who Should Consider Testing

ELP1 carrier testing is most strongly indicated for people with a known family history or a reproductive partner who carries a pathogenic ELP1 variant. It is also commonly included in screening offered to people with Ashkenazi Jewish ancestry because the founder variant is much more frequent in that population than in the general population.

Testing may be appropriate when any of the following applies:

• A parent, sibling, child, cousin, or other blood relative has familial dysautonomia.
• A relative has a known pathogenic or likely pathogenic ELP1 variant.
• A reproductive partner has tested positive as an ELP1 carrier.
• One or both partners have full or partial Ashkenazi Jewish ancestry.
• The couple wants broad preconception screening regardless of ancestry.
• A pregnancy is already underway and carrier status could affect diagnostic testing decisions.
• Donor eggs, donor sperm, or embryos are being selected and genetic compatibility is being assessed.

People do not need to have two Ashkenazi Jewish parents to benefit from testing. A person may have one Ashkenazi Jewish grandparent, mixed ancestry, uncertain family origins, adoption, or limited access to family history. Modern professional guidance increasingly supports an ancestry-neutral approach to broad carrier screening because self-reported ancestry does not always predict genetic risk accurately. A pan-ethnic panel can therefore be reasonable even when familial dysautonomia is not specifically suspected.

Timing matters more than age. Testing before pregnancy gives a couple the widest range of choices and more time to obtain partner testing, counseling, insurance authorization, and laboratory records. Testing during pregnancy can still be useful, but decisions may need to be made within a shorter window.

When a specific familial variant is known, bring a copy of the relative’s laboratory report. A verbal description such as “the familial dysautonomia gene runs in the family” is not precise enough. Testing the exact known variant is more reliable than ordering a generic panel and assuming it includes the same change.

Broader Ashkenazi Jewish carrier screening often includes ELP1 together with conditions such as Tay-Sachs disease, Canavan disease, cystic fibrosis, and others. The exact genes and variants differ by laboratory, so the panel name alone does not confirm coverage.

How Testing Is Performed

ELP1 carrier testing usually begins with a blood draw, saliva collection, or cheek swab. These samples provide germline DNA, meaning DNA that is generally present throughout the body and can be inherited. Blood is often preferred when the laboratory needs a dependable DNA quantity, but saliva and cheek swabs are convenient and usually accurate when collected correctly.

No fasting is normally required. Most medications, vitamins, foods, exercise, and menstrual timing do not affect the DNA sequence. Before a saliva test, the laboratory may ask the person not to eat, drink, smoke, chew gum, or brush teeth for about 30 minutes. Follow the kit instructions because food residue or low cell content can cause sample failure.

The overall process commonly follows these steps:

1. Pretest review. A clinician or genetics professional reviews ancestry, family history, pregnancy status, prior testing, and the partner’s results.
2. Test selection. The order specifies targeted variant testing, ELP1 sequencing, deletion and duplication analysis, or a broader carrier panel.
3. Sample collection. Blood, saliva, or cheek cells are sent to a clinical laboratory.
4. DNA analysis. The laboratory compares the ELP1 sequence with a reference sequence and classifies detected variants.
5. Result interpretation. The report describes the finding, classification, test limitations, and often a residual-risk estimate.
6. Follow-up. Positive, uncertain, or unexpected results are reviewed, and partner testing may be ordered.

Turnaround time is often about two to four weeks, though targeted testing can be faster and broad panels may take longer. Prenatal situations should be marked as time-sensitive when the order is placed.

Not all laboratories analyze ELP1 in the same way. Before testing, check whether the assay includes:

• The common c.2204+6T>C founder variant
• Full sequencing of relevant ELP1 exons and splice regions
• Detection of deletions and duplications
• Reporting of pathogenic and likely pathogenic variants
• A policy for variants of uncertain significance
• Residual-risk estimates by ancestry, when available
• Confirmation of important findings with a second method

Carrier screening is usually a one-time DNA test because a person’s inherited sequence does not change. Retesting may still be appropriate when the original test was limited, laboratory technology has improved, variant classification has changed, or a newly identified family variant was not included previously.

Understanding Positive, Negative, and Uncertain Results

The report should be interpreted in the context of the test method, family history, and partner’s status. The words “positive” and “negative” are useful only when the report also explains what was actually tested.

Result	Usual interpretation	Typical next step
Pathogenic or likely pathogenic variant found	The person is usually an ELP1 carrier when one disease-causing variant is detected and there are no signs of familial dysautonomia.	Offer testing to the reproductive partner and review the result with a genetics professional.
No pathogenic variant found	Carrier risk is reduced but not eliminated. The remaining risk depends on assay coverage and prior probability.	Review residual risk and consider broader testing if family history or partner results remain concerning.
Variant of uncertain significance	A genetic change was found, but evidence is insufficient to call it disease-causing or benign.	Do not use it alone to label someone a carrier or make irreversible reproductive decisions.
Two pathogenic or likely pathogenic variants	This may indicate familial dysautonomia, particularly if the variants are on opposite gene copies.	Prompt diagnostic evaluation, phase analysis, and specialist referral are needed.
Inconclusive or sample failure	The laboratory could not obtain a reliable result because of sample quality or a technical limitation.	Repeat collection or use another validated method.

Positive carrier result

A positive result usually identifies one pathogenic or likely pathogenic ELP1 variant. The person is expected to be healthy but can pass the variant to each child with a probability of 50%. That transmission probability does not change based on the child’s sex.

The report may use older gene terminology. ELP1 was formerly called IKBKAP, so family records and older publications may name the same gene differently. Variant descriptions can also differ by transcript or historical nomenclature. A genetics professional can determine whether two differently written results refer to the same variant.

Negative result and residual risk

A negative result means the laboratory did not find a reportable disease-causing variant within the regions and variant types it analyzed. It does not prove that the person is not a carrier. Rare variants may lie outside covered regions, evade the technology, or remain scientifically unrecognized.

Residual risk can be thought of as:

carrier probability before testing × probability that the test would miss a carrier variant

For example, if a person’s estimated pretest carrier probability were 1 in 30 and a particular assay detected 99% of carriers in that population, a simplified residual risk would be about 1 in 3,000. Actual laboratory calculations may differ because detection rates, ancestry estimates, and variant frequencies are not perfectly precise.

A negative targeted founder test is less reassuring for a person with non-Ashkenazi ancestry, mixed ancestry, or a family history involving an uncharacterized variant. In those settings, full-gene analysis may provide a more appropriate assessment.

Variant of uncertain significance

A variant of uncertain significance, or VUS, is not a positive carrier result. It should not be treated as proof that a pregnancy is at 25% risk. Laboratories may later reclassify a VUS as benign, likely benign, likely pathogenic, or pathogenic as evidence accumulates. Clinical laboratories differ in whether they report VUS findings during routine carrier screening because uncertain results can create confusion without improving care.

A genetic variant classification reflects the strength of evidence, not the severity of disease. “Likely pathogenic” generally means there is strong evidence that the variant causes disease, while “pathogenic” means the evidence is considered definitive or very strong.

Pregnancy Risk When One or Both Partners Are Carriers

Familial dysautonomia follows autosomal recessive inheritance. A child usually develops the condition only after inheriting a pathogenic ELP1 variant from both biological parents.

When one partner is a confirmed carrier and the other has a comprehensive negative result, the chance of an affected child becomes low but not zero because the negative partner retains residual carrier risk. The laboratory or genetic counselor may estimate the couple’s remaining risk by multiplying the carrier’s 50% chance of passing the variant by the other partner’s residual carrier probability and 50% transmission chance.

When both partners are confirmed carriers, every pregnancy has:

• A 25% chance of a child with familial dysautonomia
• A 50% chance of a healthy carrier child
• A 25% chance of a child who inherited neither familial variant

These probabilities reset with each pregnancy. Having one unaffected child does not make the next pregnancy safer, and having one affected child does not mean the next will also be affected.

The two parental variants do not need to be identical. A child can be affected after inheriting the common founder variant from one parent and a different pathogenic ELP1 variant from the other. This is called compound heterozygosity.

When only one partner has been tested, the couple’s risk cannot be fully defined. Testing the other biological parent is usually the most direct next step. Testing should ideally analyze the full gene or at least reliably detect the first partner’s variant and other variants relevant to the second partner’s ancestry and family history.

If both partners carry variants, reproductive options may include:

• Natural conception with diagnostic testing during pregnancy
• In vitro fertilization with preimplantation genetic testing for monogenic disease
• Use of donor egg or donor sperm from a screened non-carrier
• Use of donor embryos
• Adoption
• Natural conception without prenatal diagnosis, with preparation for postnatal testing and care
• Deciding not to pursue pregnancy

Next Steps After a Carrier Result

A carrier result is most useful when it leads to an organized follow-up plan rather than alarm. The first step is to obtain and keep the complete laboratory report, not just a portal message or verbal summary.

If one partner is positive

The reproductive partner should be offered ELP1 testing. Testing only the common founder variant may be inadequate when the partner has mixed or non-Ashkenazi ancestry, when the first person’s variant is rare, or when the laboratory’s detection rate is uncertain. A genetics professional can match the method to the situation.

If pregnancy is already underway, contact the prenatal clinician promptly so partner testing can be expedited. A positive carrier result is not a medical emergency, but delays can narrow the time available for diagnostic options.

If both partners are positive

Meet with a genetic counselor, maternal-fetal medicine specialist, reproductive endocrinologist, or medical geneticist. Confirm that both variants are pathogenic or likely pathogenic and that each person carries one variant. The team may also check whether the variants are expected to cause classic familial dysautonomia and whether the laboratory recommends additional confirmation.

During an ongoing pregnancy, diagnostic testing can determine whether the fetus inherited both variants. Chorionic villus sampling is generally performed in the first trimester, often around 10 to 13 weeks, while amniocentesis is commonly performed from about 15 weeks onward. These procedures collect fetal or placental cells for targeted variant analysis. They are diagnostic, unlike routine screening tests that estimate probability.

Preimplantation testing requires custom development of a family-specific assay in many cases. The laboratory may request DNA from both partners and sometimes affected or unaffected relatives. Starting this process before an IVF cycle can prevent avoidable delays.

Tell relatives who may also be carriers

Biological siblings of a carrier may have an increased chance of carrying the same familial variant. Parents, adult children, aunts, uncles, and cousins may also benefit from knowing that a documented ELP1 variant is present in the family. Sharing a copy of the report is more useful than sharing only the gene name.

A carrier’s existing children are not automatically affected. If the other biological parent is not a carrier, each child still has a 50% chance of being a carrier. The appropriate age and setting for testing healthy minors should be discussed with a genetics professional.

Keep results available over time

Save the report in a secure location and include the exact gene, variant, classification, laboratory, and date. Variant classifications and test methods change. Some laboratories offer updates or reanalysis, but policies differ. A result from many years ago may deserve review before a new pregnancy, especially if it was based on a small ancestry panel.

Test Limitations and Common Mistakes

Carrier testing is highly informative, but its accuracy depends on matching the test to the clinical question. Several common errors can create false reassurance or unnecessary fear.

Mistake: assuming every “Ashkenazi panel” is the same. Panel content varies widely. Some tests examine a small group of founder variants, while others sequence many genes. Confirm that ELP1 is included and identify which variant types are covered.

Mistake: calling a negative result “zero risk.” Every negative carrier screen leaves residual risk. The size of that risk depends on ancestry, family history, variant frequency, and detection rate.

Mistake: testing only one partner and stopping. A positive result becomes clinically actionable when the other biological parent is tested. Without partner testing, the couple’s risk remains uncertain.

Mistake: treating a VUS as pathogenic. An uncertain variant should not be used by itself to diagnose carrier status, test a pregnancy, or select embryos. Clarification may require laboratory review, family studies, or later reclassification.

Mistake: relying on a relative’s recollection. Families may confuse familial dysautonomia with other neuropathies or use an outdated gene name. Obtain the actual molecular report whenever possible.

Mistake: assuming ancestry excludes risk. Familial dysautonomia is strongly associated with Ashkenazi Jewish ancestry, but rare pathogenic ELP1 variants can occur in other populations. Family history and partner results may justify comprehensive testing regardless of ancestry.

Mistake: confusing carrier screening with diagnostic testing. A carrier assay is designed for people without signs of disease. A child or adult with symptoms consistent with familial dysautonomia needs a diagnostic evaluation, which may include comprehensive ELP1 analysis and assessment for other hereditary sensory and autonomic neuropathies.

Mistake: using a negative expanded panel to rule out every inherited condition. No panel covers all genes, all variant types, or all diseases. An expanded carrier screening test can reduce risk for the conditions included, but it cannot guarantee a child without genetic disease.

Technical limitations may include low coverage in certain regions, difficulty detecting deep intronic changes, structural variants, mosaicism, or variants whose significance is not yet known. Laboratories should disclose these limitations in the report. When the family history is strong and routine testing is negative, consultation with a medical geneticist may identify a better method, such as broader sequencing, RNA studies, or testing an affected relative first.

Questions to Ask Before and After Testing

Good questions help ensure that the result answers the intended problem. Before ordering the test, ask:

• Is this targeted testing, full ELP1 sequencing, or part of a broad panel?
• Does it include the c.2204+6T>C founder variant and other relevant ELP1 variants?
• Does the laboratory assess deletions and duplications?
• What detection rate applies to my ancestry and family history?
• Will the laboratory report variants of uncertain significance?
• What will my residual carrier risk be after a negative result?
• Should my partner be tested at the same time or only if my result is positive?
• How long will results take, and can testing be expedited during pregnancy?
• Is genetic counseling included or billed separately?
• What documents are needed if a relative has a known variant?

After receiving the result, ask:

• Is the finding classified as pathogenic, likely pathogenic, or uncertain?
• Does the report confirm carrier status, or is additional testing needed?
• Was only one variant found, and could a second variant have been missed?
• Which test should my partner receive?
• What is our numerical chance of an affected pregnancy?
• Are prenatal diagnosis or PGT-M technically available for our specific variants?
• Should adult relatives be offered targeted testing?
• Will the laboratory contact us if the variant classification changes?
• Should an older negative result be repeated with a more comprehensive method?

References

• Familial Dysautonomia 2021 (Review)
• Familial dysautonomia 2023 (Review)
• ELP1, the Gene Mutated in Familial Dysautonomia, Is Required for Normal Enteric Nervous System Development and Maintenance, and for Gut Epithelium Homeostasis 2024
• Screening for autosomal recessive and X-linked conditions during pregnancy and preconception: a practice resource of the American College of Medical Genetics and Genomics (ACMG) 2021 (Practice Resource)
• Laboratory testing for preconception/prenatal carrier screening: A technical standard of the American College of Medical Genetics and Genomics (ACMG) 2024 (Technical Standard)
• Familial dysautonomia 2024

Disclaimer

This information is educational and does not replace individualized genetic counseling or medical care. Carrier risk, residual risk, and reproductive options depend on the exact ELP1 variant, laboratory method, family history, ancestry, and partner’s result. Discuss positive, uncertain, or time-sensitive pregnancy results with a qualified genetics or prenatal specialist.